Chimeric antigen receptor T‐cell therapy combined with autologous stem cell transplantation improved progression‐free survival of relapsed or refractory diffuse large B‐cell lymphoma patients: A single‐center, retrospective, cohort study
Authors:
- 9 February 2022
- journal article
- research article
- Published by Wiley in Hematological Oncology
- Vol. 40 (4) , 637-644
Abstract
Autologous hematopoietic stem cell transplantation (ASCT) and chimeric antigen receptor T‐cell therapy (CART) are salvage therapies that are utilised for treatment of relapsed or refractory (R/R) diffuse large B‐cell lymphoma (DLBCL). However, whether the combination therapy of ASCT and CART (ASCT‐CART) can improve the survival of R/R DLBCL remains unknown. Overall, 67 R/R DLBCL patients were included, among which 21 patients underwent ASCT‐CART therapy and 46 patients underwent ASCT therapy. The median number of mononuclear cells numbers that were infused in the ASCT‐CART and ASCT groups was 4.71 × 108/kg and 5.36 × 108/kg, respectively (p = 0.469). The median number of CD34+ cell numbers that were infused in the ASCT‐CART and ASCT groups was 2.41 × 106/kg and 3.05 × 106/kg, respectively (p = 0.663). The median number of CART cells that were infused was 2.63 × 106/kg with a median transduction rate of 59.83%. The objective response rates to ASCT‐CART and ASCT therapy were 90% and 89%, respectively (p = 1.000). However, the ASCT‐CART group showed higher complete remission (CR) rates than the ASCT group (71% vs. 33%; p = 0.003). The ASCT‐CART group demonstrated superior 3 year progression‐free survival (PFS) (80% vs. 44%; p = 0.036) and lower 3 year relapse/progression rate (15% vs. 56%; p = 0.015) compared to the ASCT group. However, the 3 year overall survival results indicated that there were no differences between the two groups (80% vs. 69%; p = 0.545). For R/R DLBCL patients, ASCT‐CART therapy is associated with higher CR rate, better PFS, and lower relapse/progression rate. These data support that ASCT‐CART therapy can be used as a salvage therapy for R/R DLBCL patients.Keywords
Funding Information
- National Natural Science Foundation of China (81770209)
This publication has 27 references indexed in Scilit:
- Validity and Reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)JAMA Oncology, 2015
- Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL studyBone Marrow Transplantation, 2015
- Non‐Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011American Journal of Hematology, 2015
- Current concepts in the diagnosis and management of cytokine release syndromeBlood, 2014
- Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 2013
- Outcomes of patients with relapsed/refractory diffuse large B‐cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab eraAmerican Journal of Hematology, 2013
- Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'AdulteBlood, 2010
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'AdulteJournal of Clinical Oncology, 2005
- Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin's lymphoma not achieving complete response after induction chemotherapy: the GEL/TAMO experienceAnnals of Oncology, 2004